Author

T. Abrams

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Approach:benchmark study· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Kauffmann· 1 shared A. W. Ying· 1 shared C. Kadoch· 1 shared C. R. Vakoc· 1 shared D. A. Ruddy· 1 shared E. Kurth· 1 shared E. Mazzola· 1 shared E. R. McDonald· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Kauffmann

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer

L. Duplaquet, K. So, A. W. Ying, X. Li, Y. Li, X. Qiu, R. Li, S. Singh, X. S. Wu, Q. Liu, J. Qi, T. D. D. Somerville, H. Heiling, E. Mazzola, Y. Lee, , M. G. Oser

This study identifies mSWI/SNF complex activity as a targetable dependency in POU2F3-positive small cell lung cancer, showing that inhibiting mSWI/SNF or BRD9 reduces tumor growth and improves survival.

bioRxiv · Jan 21, 2024Cancer Biology

Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia

F. Rago, L. U. Rodrigues, M. Bonney, K. Sprouffske, E. Kurth, G. Elliott, J. Ambrose, P. Aspesi, J. Oborski, J. T. Chen, E. R. McDonald, F. A. Mapa, D. A. Ruddy, A. Kauffmann, T. Abrams, , Z. Jagani

This study shows that dual BRG1/BRM ATPase inhibitors are effective against AML cell lines, revealing broad SWI/SNF dependencies and suggesting therapeutic potential.

bioRxiv · Apr 23, 2021Cancer Biology